Biotech · Public company · Boston, MA, US

Aktis Oncology, Inc.

Ticker AKTS · SEC CIK 0002035832

Track this companyFree. Adds Aktis Oncology, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials33 recruiting or active

Pipeline programs6From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline6

[225Ac]Ac-AKY-1189 (therapeutic)Phase 1 · Urothelial Carcinoma BladderClinicalTrials.gov · fetched Nov 12, 2026
[225Ac]Ac-AKY-2519 (therapeutic)Phase 1 · Castration Resistant Metastatic Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
[225Ac]Ac-AKY-2519 (therapeutic)Phase 1 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
[64Cu]Cu-AKY-1189 (imaging)Phase 1 · Urothelial Carcinoma BladderClinicalTrials.gov · fetched Nov 12, 2026
[64Cu]Cu-AKY-2519 (imaging)Phase 1 · Castration Resistant Metastatic Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
[64Cu]Cu-AKY-2519 (imaging)Phase 1 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026

A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid TumorsPHASE1 · RECRUITING · started Nov 1, 2026ClinicalTrials.gov NCT07887971 · fetched Nov 12, 2026
A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate CancerPHASE1 · RECRUITING · started Jun 17, 2026ClinicalTrials.gov NCT07581184 · fetched Nov 12, 2026
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid TumorsPHASE1 · RECRUITING · started Aug 22, 2025ClinicalTrials.gov NCT07020117 · fetched Nov 12, 2026